Aequilibrium Express technology changes the paradigm of recombinant-protein manufacture. Traditional production-scale processes rely on bacterial, yeast, or mammalian cell-culture expression systems, transgenic animals, or purification from natural sources. The limitations of these approaches include inadequate or non-sustainable supply from naturally occurring sources; low manufacturing yields with high capital-investment requirements and operating costs, and associated high cost of production; and potential for contamination from by-products present in the background organism or natural source.
Eukaryotic expression system: plants can manufacture complex biologics that are difficult to make in other hosts, including proteins requiring post-translational modification.
Flexibility: ability to manufacture multi-subunit molecules, monoclonal antibodies, fusion proteins, and enzymes.
Purity: products that are inherently free of animal, human, or microbial by-products, making them ideal for therapeutic use or for use in sensitive and exacting biotechnology applications.
Cost-effectiveness: suitable for cGMP manufacturing with dramatically lower cost of production.
Scalability: recombinant protein yields from kilograms to hundreds of metric tons.
Simplicity: batch-purification uses a simple, scalable, aqueous process with a 12 to 16-hour batch time.